Observation And Analysis Of The Curative Effect Of Sacubatre And Valsartan Sodium On Chronic Heart Failure

Objective: To evaluate the effectiveness and safety of the drug by observing and analyzing some tests,examination indexes and adverse events of salkubatrov in patients with chronic heart failure,so as to provide strong evidence for the treatment of patients with chronic heart failure.Methods: A total of 152 hospitalized patients with chronic heart failure who were diagnosed in the First Affiliated Hospital of China University of science and Technology(Anhui Provincial Hospital)of Wannan Medical College from June 2019 to March 2020 were selected and divided into control group(n = 50)and experimental group(n = 102)according to the drug use,The gender,age,height,weight,history of diabetes,hypertension,history of coronary heart disease,etiology and current drug use of each patient were collected,and the data of blood urea nitrogen(BUN),creatinine(crea),N-terminal B-type natriuretic peptide precursor(NT pro BNP),high-sensitivity troponin I(tniu),cardiac color Doppler ultrasound(SPAP),blood pressure(HR),blood pressure(HR),blood pressure(HR)were improved before treatment Left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDV),interventricular septal thickness(ivst),6-minute walk test(6MWT)and Minnesota Heart Failure specific quality of life questionnaire(mlhfq score)were compared between the two groups,Adverse events(including adverse drug reactions,target organ damage,hypotension,arrhythmia,hyperkalemia,rehospitalization of heart failure and death)were collected.Results: 1.Through the comparative analysis of the data of the control group and the experimental group before treatment,the basic data of the two groups were similar,without statistical difference;2.Through the comparison of the control group before treatment and 3 months and 6 months after treatment,it was found that the differences of NT pro BNP,LVEF,LVEDV,6MWT and mlhfq scores in the control group were statistically significant(P < 0.05);3 By comparing the scores of bun,crea,NT pro BNP,tniu,SPAP,LVEF,ivst,LVEDV,6MWT and mlhfq in the experimental group before treatment and 3 months and 6 months after treatment,it was found that there were statistically significant differences in the scores of bun,crea,NT pro BNP,tniu,SPAP,LVEF,ivst,LVEDV,6MWT and mlhfq between the two groups(P < 0.05);4 There were significant differences in the scores of bun,crea,NT pro BNP,tniu,LVEF,ivst,LVEDV,6MWT and mlhfq between the experimental group and the control group 6 months after treatment(P < 0.05);6.The scores of bun,crea,NT pro BNP,tniu,SPAP,LVEF,ivst and l-probnp before and 6 months after treatment in the experimental group were compared with those in the control group The scores of ivst,LVEDV,6MWT and mlhfq between the two groups were statistically significant(P < 0.05).The scores of bun,crea,NT pro BNP,tniu,SPAP,LVEF,ivst,LVEDV,6MWT and mlhfq between the experimental group and the control group were statistically significant(P < 0.05)U.The differences of SPAP,LVEF,ivst,LVEDV and mlhfq scores were statistically significant(P < 0.05).7.Through the collection and comparison of adverse events in the experimental group and the control group within 6 months after treatment,the results showed that the safety of Arni was no different from that of valsartan(P > 0.05),and the incidence of arrhythmia and rehospitalization rate of patients taking Arni was lower than that of valsartan(P <0.05).Conclusion: for patients with chronic heart failure,the quality of life of the patients can be improved,long-term administration can reverse ventricular remodeling and improve renal function,so as to reduce the incidence of arrhythmia and rehospitalization rate,the effect is better than valsartan,and the safety is reliable,which is convenient for clinical application.